ClinicalTrials.gg
TerminatedNCT01168791PICASSO IIIUpdated Oct 6, 2026

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

A Phase 3 interventional study of Palifosfamide-Tris and doxorubicin in Soft Tissue Sarcoma, sponsored by Alaunos Therapeutics. Terminated at 161 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Alaunos Therapeutics · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Primary endpoint (PFS) not met at the final analysis; sponsor decided to stop the study before the planned final overall survival analysis.
Updated Oct 1, 2026Now TerminatedInterventions changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
447
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
21st of 800
447 · median 35
Started
2010
with 34 others
Phase 3
38 of 958
2 open now
Registered
365th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 21st largest by enrollment of the 800 interventional ones that give a count, is one of 35 that started in 2010, is one of 38 in phase 3, and was the 365th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).

03

Conditions studied

  • Soft Tissue Sarcoma

Keywords

  • Metastatic
  • Front line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible, each patient must meet EACH of the following criteria:

  • Age ≥18 years.
  • Documented soft tissue sarcoma
  • disease for which the patient has not received any prior treatment, and for whom treatment with doxorubicin is considered medically acceptable.
  • Performance Status of 0, 1 or 2
  • Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests
  • Male and female patients must agree to use a highly reliable method of during study participation.
  • Able to provide

To be eligible, each patient must meet NONE of the following criteria:

  • Specific sarcoma histological subtypes including GIST and Ewing's sarcoma.
  • Systemic therapy for the treatment of metastatic sarcoma, prior to or during the study. However, patients may have received /adjuvant Gemzar and Taxotere chemotherapy for their primary sarcoma, prior to the development of metastatic disease
  • Any prior anthracycline use.
  • Known allergy to any of the study drugs or their .
  • Any unstable or concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
  • Myocardial dysfunction defined as (LVEF) \<50%.
  • Documented metastases to brain or meninges.
  • Any other than sarcoma within the last 5 years prior to screening, with the exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease.
  • Currently pregnant or nursing.
  • Radiotherapy with curative intent within 4 weeks of first dose of study drug.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
447 participants (actual)

Study arms

  • Experimental
    doxorubicin plus palifosfamide-tris

    Participants received doxorubicin 75 mg/m² IV on Day 1 plus palifosfamide-tris 150 mg/m² IV on Days 1, 2, and 3 of each 21-day cycle for a maximum of 6 cycles.

    Drug: Palifosfamide-Tris · Drug: doxorubicin

  • Active comparator
    doxorubicin plus placebo

    Participants received doxorubicin 75 mg/m² IV on Day 1 plus placebo IV on Days 1, 2, and 3 of each 21-day cycle for a maximum of 6 cycles.

    Drug: doxorubicin · Drug: Placebo

Interventions

  • DrugIsophosphamide mustardStudies of Isophosphamide mustardIsophosphamide mustard pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Palifosfamide-tris 150 mg/m² administered intravenously on Days 1, 2, and 3 of each 21-day cycle for a maximum of 6 cycles.

    Also known as: ZIO-201, isophosphoramide mustard

  • Doxorubicin 75 mg/m² administered intravenously on Day 1 of each 21-day cycle for a maximum of 6 cycles.

    Also known as: Adriamycin

  • DrugPlacebo

    250 mL normal saline administered intravenously on Days 1, 2, and 3 of each 21-day cycle for a maximum of 6 cycles.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival followed by Overall Survival

    Time frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death

Secondary outcomes

  1. Quality of Life, as assessed by EORTC QLQ-C30 and EQ-5D questionnaires

    Time frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months, then every 12 weeks until death

  2. Safety and Tolerability as evaluated using CTCAE v 4.0

    Time frame: 22 weeks

07

Study locations

161 sites
  • Birmingham, Alabama, United States
  • Arizona Oncology Associates
    Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • University of California, Los Angeles
    Los Angeles, California, United States
  • Los Angeles, California, United States
  • University of California, Irvine
    Orange, California, United States
  • Pomona, California, United States
  • Sarcoma Oncology Center
    Santa Monica, California, United States
  • University of Colorado Cancer Center
    Aurora, Colorado, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado, United States
  • Medical Oncology Hematology Consultants
    Newark, Delaware, United States
  • MedStar Research Institute
    Washington D.C., District of Columbia, United States
  • Washington D.C., District of Columbia, United States
  • Jacksonville, Florida, United States
  • Orlando, Florida, United States
  • Moffitt Cancer Center
    Tampa, Florida, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida, United States
  • Emory
    Atlanta, Georgia, United States
  • Medical College of Georgia
    Augusta, Georgia, United States
  • Kootenai Cancer Center
    Post Falls, Idaho 83854, United States
  • Chicago, Illinois, United States
  • Park Ridge, Illinois, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa, United States
  • Kansas City Cancer Center
    Overland Park, Kansas, United States
  • New Orleans, Louisiana, United States
  • LSU Health Sciences Center, Feist-Weiller Cancer Center
    Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Mayo Clinic
    Rochester, Minnesota, United States
  • St.Louis University
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine
    St Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Hackensack, New Jersey, United States
  • Morristown, New Jersey, United States
  • Saint Barnabas
    West Orange, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York, United States
  • University of Rochester
    Rochester, New York, United States
  • The Bronx, New York, United States
  • University of North Carolina
    Chapel Hill, North Carolina, United States
  • Durham, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina, United States
  • Summa Health System
    Akron, Ohio, United States
  • UC Cancer Institute
    Cincinnati, Ohio, United States
  • Cleveland Clinic
    Cleveland, Ohio, United States
  • The Ohio State University Medical Center
    Columbus, Ohio, United States
  • Cancer Care Associates
    Tulsa, Oklahoma, United States
  • Oregon Health and Science University
    Portland, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Pennsylvania Oncology/Hematology Associates
    Philadelphia, Pennsylvania, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
  • Providence, Rhode Island, United States
  • Charleston, South Carolina, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Texas Oncology
    Bedford, Texas, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 8229, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia, United States
  • University of Washington/Seattle Cancer Care Alliance
    Seattle, Washington, United States
  • Bellin Cancer Center
    Green Bay, Wisconsin 54313, United States
  • University of Wisconsin
    Madison, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • Ciudad de Buenos Aires, Argentina
  • Córdoba, Argentina
  • Ramos Mejía, Argentina
  • Instituto CAICI
    Rosario, Argentina
  • Sante Fe, Argentina
  • North Adelaide Oncology
    Adelaide, SA 5006, Australia
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Camperdown, Australia
  • East Melbourne, Australia
  • The Canberra Hospital
    Garran, Australia
  • Garran, Australia
  • Kurralta Park, Australia
  • Nedlands, Australia
  • Prince of Wales Hospital
    Randwick, NSW 2031, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Antwerp, Belgium
  • Brussels, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Institution name: Hospital de Câncer de Barretos - Fundação PIOXII
    Barretos, Brazil
  • Belo Horizonte, Brazil
  • Santa Casa da Misericórdia de Curitiba
    Curitiba, Brazil
  • Florianópolis, Brazil
  • Jaú, Brazil
  • Hospital da Cidade de Passo Fundo
    Passo Fundo, Brazil
  • Hospital das Clínicas de Porto Alegre
    Porto Alegre, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, Brazil

Showing the first 100 of 161 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schoffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30. PubMed 27621408 ↗
09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2010 to primary completion in Mar 2013, 30 months.

Start moved once since we started tracking on Sep 25, 2026: Jul 2010 → Aug 2010, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2010
First posted
Jul 23, 2010
StartActual
Aug 16, 2010was Jul 2010
Primary completionActual
Mar 13, 2013
CompletionActual
Mar 13, 2013
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Primary endpoint (PFS) not met at the final analysis; sponsor decided to stop the study before the planned final overall survival analysis.
changed Sep 30, 2026
Sites
32 sites added, 33 sites removed
Show 32 added (9 United States, 3 Brazil, 3 Colombia, 3 Germany, 2 Argentina, 2 Belgium, 2 Panama, 1 Chile, 1 France, 1 Guatemala, 1 India, 1 Israel, 1 Poland, 1 Romania, 1 Russia)
  • MedStar Research Institute · Washington D.C., United States
  • Washington D.C. · Washington D.C., United States
  • Indiana University Simon Cancer Center · Indianapolis, United States
  • St.Louis University · St Louis, United States
  • Washington University School of Medicine · St Louis, United States
  • The Bronx · The Bronx, United States
  • UC Cancer Institute · Cincinnati, United States
  • Bethlehem · Bethlehem, United States
  • University of Pittsburgh · Pittsburgh, United States
  • Córdoba · Córdoba, Argentina
  • Ramos Mejía · Ramos Mejía, Argentina
  • Brussels · Brussels, Belgium
  • Liège · Liège, Belgium
  • Florianópolis · Florianópolis, Brazil
  • Jaú · Jaú, Brazil
  • São Paulo · São Paulo, Brazil
  • Viña del Mar · Viña del Mar, Chile
  • Bogotá · Bogotá, Colombia
  • Medellín · Medellín, Colombia
  • Montería · Montería, Colombia
  • Institut Paoli Calmettes · Marseille, France
  • Universitätsklinikum Köln · Cologne, Germany
  • Hanover · Hanover, Germany
  • Tuebingen University Hospital · Tübingen, Germany
  • Guatemala City · Guatemala City, Guatemala
  • Nashik · Nashik, India
  • Petah Tikva · Petah Tikva, Israel
  • Centro Hemato Oncologico Paitilla · Panama City, Panama
  • Medical and Research Center · Panama City, Panama
  • Centrum Onkologii Instytut · Warsaw, Poland
  • …and 2 more on the registry record
Show 33 removed
  • MedStar Research Institute · Washington, United States
  • Washington · Washington, United States
  • Indiana University Simon Cancer Center · Indiannapolis, United States
  • St.Louis University · St. Louis, United States
  • Washington University School of Medicine · St. Louis, United States
  • Bronx · Bronx, United States
  • UC Cancer Institute · Cinncinnati, United States
  • Bethelehem · Bethelehem, United States
  • University of Pittsburgh · Pittsburg, United States
  • Cordoba · Cordoba, Argentina
  • Ramos Mejia · Ramos Mejia, Argentina
  • Bruxelles · Bruxelles, Belgium
  • Liege · Liege, Belgium
  • Florianopolis · Florianopolis, Brazil
  • Jau · Jau, Brazil
  • Sao Paulo · Sao Paulo, Brazil
  • Vina del Mar · Vina del Mar, Chile
  • Bogota · Bogota, Colombia
  • Medellin · Medellin, Colombia
  • Monteria · Monteria, Colombia
  • Institut Paoli Calmettes · Marseilles, France
  • Hannover · Hannover, Germany
  • Universitätsklinikum Köln · Koln, Germany
  • Tuebingen University Hospital · Tuebingen, Germany
  • Guatemala · Guatemala, Guatemala
  • Nasik · Nasik, India
  • Petach Tikva · Petach Tikva, Israel
  • Ramat-Gan · Ramat-Gan, Israel
  • Centro Hemato Oncologico Paitilla · Panama, Panama
  • Medical and Research Center · Panama, Panama
  • …and 3 more on the registry record
Sep 30, 2026
Start date
Jul 2010→Aug 16, 2010 (actual)
Sep 30, 2026
Interventions
Added Drug: Palifosfamide-Tris·Drug: doxorubicin·Drug: Placebo; removed Drug: doxorubicin in combination with palifosfamide-tris·Drug: doxorubicin in combination with placebo
Oct 1, 2026
Show all 4 updates
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: arm descriptions
  2. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and arm descriptions
  3. Oct 1, 2026
    Interventions Added Drug: Palifosfamide-Tris·Drug: doxorubicin·Drug: Placebo; removed Drug: doxorubicin in combination with palifosfamide-tris·Drug: doxorubicin in combination with placebo
    + 1 other change: index terms
  4. Sep 30, 2026
    Completed→Terminated
    Why stopped Primary endpoint (PFS) not met at the final analysis; sponsor decided to stop the study before the planned final overall survival analysis.
    32 sites added, 33 sites removed
    Show 32 added (9 United States, 3 Brazil, 3 Colombia, 3 Germany, 2 Argentina, 2 Belgium, 2 Panama, 1 Chile, 1 France, 1 Guatemala, 1 India, 1 Israel, 1 Poland, 1 Romania, 1 Russia)
    • MedStar Research Institute · Washington D.C., United States
    • Washington D.C. · Washington D.C., United States
    • Indiana University Simon Cancer Center · Indianapolis, United States
    • St.Louis University · St Louis, United States
    • Washington University School of Medicine · St Louis, United States
    • The Bronx · The Bronx, United States
    • UC Cancer Institute · Cincinnati, United States
    • Bethlehem · Bethlehem, United States
    • University of Pittsburgh · Pittsburgh, United States
    • Córdoba · Córdoba, Argentina
    • Ramos Mejía · Ramos Mejía, Argentina
    • Brussels · Brussels, Belgium
    • Liège · Liège, Belgium
    • Florianópolis · Florianópolis, Brazil
    • Jaú · Jaú, Brazil
    • São Paulo · São Paulo, Brazil
    • Viña del Mar · Viña del Mar, Chile
    • Bogotá · Bogotá, Colombia
    • Medellín · Medellín, Colombia
    • Montería · Montería, Colombia
    • Institut Paoli Calmettes · Marseille, France
    • Universitätsklinikum Köln · Cologne, Germany
    • Hanover · Hanover, Germany
    • Tuebingen University Hospital · Tübingen, Germany
    • Guatemala City · Guatemala City, Guatemala
    • Nashik · Nashik, India
    • Petah Tikva · Petah Tikva, Israel
    • Centro Hemato Oncologico Paitilla · Panama City, Panama
    • Medical and Research Center · Panama City, Panama
    • Centrum Onkologii Instytut · Warsaw, Poland
    • …and 2 more on the registry record
    Show 33 removed
    • MedStar Research Institute · Washington, United States
    • Washington · Washington, United States
    • Indiana University Simon Cancer Center · Indiannapolis, United States
    • St.Louis University · St. Louis, United States
    • Washington University School of Medicine · St. Louis, United States
    • Bronx · Bronx, United States
    • UC Cancer Institute · Cinncinnati, United States
    • Bethelehem · Bethelehem, United States
    • University of Pittsburgh · Pittsburg, United States
    • Cordoba · Cordoba, Argentina
    • Ramos Mejia · Ramos Mejia, Argentina
    • Bruxelles · Bruxelles, Belgium
    • Liege · Liege, Belgium
    • Florianopolis · Florianopolis, Brazil
    • Jau · Jau, Brazil
    • Sao Paulo · Sao Paulo, Brazil
    • Vina del Mar · Vina del Mar, Chile
    • Bogota · Bogota, Colombia
    • Medellin · Medellin, Colombia
    • Monteria · Monteria, Colombia
    • Institut Paoli Calmettes · Marseilles, France
    • Hannover · Hannover, Germany
    • Universitätsklinikum Köln · Koln, Germany
    • Tuebingen University Hospital · Tuebingen, Germany
    • Guatemala · Guatemala, Guatemala
    • Nasik · Nasik, India
    • Petach Tikva · Petach Tikva, Israel
    • Ramat-Gan · Ramat-Gan, Israel
    • Centro Hemato Oncologico Paitilla · Panama, Panama
    • Medical and Research Center · Panama, Panama
    • …and 3 more on the registry record
    Start date Jul 2010→Aug 16, 2010 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01168791
Responsible party
Sponsor
First posted
Jul 23, 2010
Start date
Aug 16, 2010
Primary completion
Mar 13, 2013
Completion
Mar 13, 2013
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isophosphamide mustard

Start the discussion